Lv42
482 积分 2023-09-04 加入
Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection
49分钟前
已完结
ALG ‐020572, an Antisense Oligonucleotide for the Treatment of Chronic Hepatitis B Virus Infection Discontinued for Drug‐Induced Liver Injury
6天前
已完结
OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
25天前
已完结
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study
25天前
已完结
Mechanism of action and treatment of type I interferon in hepatocellular carcinoma
1个月前
已完结
Discovery of hepatitis B virus subviral particle biogenesis inhibitors from a bioactive compound library
1个月前
已完结
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed
2个月前
已完结
The SWI/SNF complex mediated chromatin remodeling promotes hepatitis B virus cccDNA transcription
2个月前
已完结
HBx-induced HSPB1 is a potential therapeutic target owing to its modulation of HBV cccDNA and hepatic immune responses
2个月前
已完结
Interferon Therapy for Hypertrophic Scars and Keloids
2个月前
已关闭
皖公网安备34019202002308
